A randomized trial evaluates rapid molecular testing in suspected ventilator-associated pneumonia and finds that targeted therapy is started earlier only when cultures confirm infection, without improving overall prognostic outcomes. The results point to the importance of diagnostic accuracy and confirmatory workflows rather than relying on early initiation alone.